FDA Approves Imcivree (Setmelanotide) — Supplemental Approval — Efficacy [Priority Review]

FDA19 Mar 2026·Supplemental Approval — Efficacy [Priority Review]● 6/10i

FDA Approves Imcivree (Setmelanotide) — Supplemental Approval — Efficacy [Priority Review]

Rhythm

FDA approved a supplemental application for Imcivree (setmelanotide, Rhythm) on March 19, 2026, under priority review. This represents an efficacy-based label expansion for the melanocortin-4 receptor agonist, which was initially approved for rare genetic obesity disorders. Rhythm gains additional indication breadth in the specialized rare obesity market, where treatment options remain extremely limited. The priority review designation signals FDA recognition of significant unmet medical need in the expanded patient population.

Strategic signal

Rhythm expands its rare obesity franchise with limited competitive overlap, positioning for premium orphan pricing across a broader patient base. The priority review suggests FDA urgency around unmet need, potentially accelerating commercial timelines and supporting reimbursement discussions with specialized payers. This mirrors the rare disease playbook where indication expansion drives revenue growth through patient identification and diagnostic improvements rather than market share battles.

Weight lossOtherRhythm

Original Abstract

View original source ↗

Related signals

ClinicalTrials19 Mar 2026·Phase 3● 9/10iHigh impact

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Phase 3 SURMOUNT-1 tests once-weekly tirzepatide at three doses versus placebo in adults without type 2 diabetes who have obesity or are overweight with comorbidities. The randomized, double-blind trial targets 2,539 participants with primary efficacy assessment at 72 weeks. This represents tirzepatide's pivotal obesity trial against placebo, potentially supporting Eli Lilly's bid to compete directly with Wegovy in the non-diabetic obesity market. A prediabetes subgroup continues long-term to assess diabetes prevention.

Weight lossGLP-1Eli Lilly

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly

ClinicalTrials16 Apr 2026·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 master protocol testing oral orforglipron versus placebo in adults with obesity or overweight, with or without type 2 diabetes. Enrolling 1,200 participants across two sub-studies, expected completion August 2027, placebo-controlled design. Eli Lilly advances orforglipron into obesity treatment following its April 2026 FDA approval for type 2 diabetes, representing the first small-molecule oral GLP-1 to enter weight management. This positions Eli Lilly to challenge Novo Nordisk's dominance in oral GLP-1 obesity treatment, where oral semaglutide gained approval in January 2026.

GLP-1Weight lossType 2 diabetesEli Lilly Novo Nordisk